Cetuximab treatment alters the content of extracellular vesicles released from tumor cells-Reference-Cited by-同舟云学术

Cetuximab treatment alters the content of extracellular vesicles released from tumor cells

Published:2016-04 Issue:8 Volume:11 Page:881-890
ISSN:1743-5889
Container-title:Nanomedicine
language:en
Short-container-title:Nanomedicine

Author:

van Dommelen Susan M¹,van der Meel Roy¹²,van Solinge Wouter W¹,Coimbra Maria³,Vader Pieter¹,Schiffelers Raymond M¹

Affiliation:

1. Department of Clinical Chemistry & Haematology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands

2. Department of Biochemistry & Molecular Biology, The University of British Columbia, Vancouver, BC, V6T 1Z3, Canada

3. Department of Pharmaceutics, Utrecht University, Universiteitsweg 99, 3584 CG Utrecht, The Netherlands

Abstract

Aim: Extracellular vesicles (EVs) are attractive candidates for biomarker research, because their content reflects the parental cell status. This study aimed to examine whether tumor cell derived EVs mirrored the cellular changes caused by treatment with cetuximab, a therapeutic antibody that blocks activation of EGF receptor (EGFR). Materials & methods: A-431 cells were treated with cetuximab for 48 h. EVs were isolated using differential centrifugation and protein content was analyzed using western blotting. Results: EV levels of EGFR and phospho-EGFR were reduced after cetuximab treatment, reflecting similar changes in the parental cells. In addition, cetuximab was found associated with EVs. Conclusion: EVs could serve as biomarkers to monitor cetuximab treatment. Association of cetuximab with EVs might influence its behavior.

Publisher

Future Medicine Ltd

Subject

Development,General Materials Science,Biomedical Engineering,Medicine (miscellaneous),Bioengineering

Link

https://www.futuremedicine.com/doi/pdf/10.2217/nnm-2015-0009

Reference39 articles.

1. Overexpression of epidermal growth factor receptor as a prognostic factor in colorectal cancer on the basis of the Allred scoring system

2. Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery

3. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

4. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells.

5. Peng D, Fan Z, Lu Y, Deblasio T, Scher H, Mendelsohn J. Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Up-Regulates p27 KIP1 and Induces G 1 Arrest in Prostatic Cancer Cell Line DU145 Advances in Brief Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Up-Regulates p27KIP1 and Induces (1996). http://cancerres.aacrjournals.org/content/56/16/3666.full.pdf.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exosomes in Cancer Progression and Therapy Resistance: Molecular Insights and Therapeutic Opportunities;Life;2023-10-09

2. The Microbiota of Brazilian Mangroves;Brazilian Mangroves and Salt Marshes;2023

3. Currently available molecular analyses for personalized tumor therapy (Review);Biomedical Reports;2022-10-14

4. Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment;Journal of Controlled Release;2022-09

5. Ubiquinone Metabolism and Transcription HIF-1 Targets Pathway Are Toxicity Signature Pathways Present in Extracellular Vesicles of Paraquat-Exposed Human Brain Microvascular Endothelial Cells;International Journal of Molecular Sciences;2021-05-11